Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

MRC Technology and AICR Partnership Reports Success for Cancer Research

Published: Wednesday, February 27, 2013
Last Updated: Wednesday, February 27, 2013
Bookmark and Share
MRC Technology reports first year highlights in supporting AICR’s technology transfer and IP management.

MRC Technology has reported successful results from the first year of its agreement with the Association for International Cancer Research (AICR).

The partnership enables AICR to take advantage of MRC Technology’s IP management, technology transfer, and drug discovery expertise, to help maximize the health benefits and revenue derived from AICR-funded research.

Over the year, MRC Technology’s experts reviewed and monitored 25 priority projects from AICR’s overall portfolio, advising on development and commercialization as appropriate.

For three of these projects, MRC Technology negotiated revenue share agreements on behalf of AICR with the universities holding the grants.

Each of these agreements reflects the value of the support given by AICR towards the success and commercialization of the research.

Mike Johnson, MRC Technology’s Director of Corporate Partnerships commented: “The success of this relationship is based on the ability of MRC Technology to add value to AICR’s mission, ensuring that research funded by the organization creates potential new health benefits wherever possible. We look forward to continuing our work with AICR, and to building similar partnerships with other charities and universities.”

Dr Helen Rippon, Head of Science at AICR commented, “We very much value our partnership with MRC Technology, and recognize their expertise in managing and commercializing IP. We are a small team at AICR, and only through our partnership with MRC Technology can we ensure that opportunities are not missed for AICR-funded research to be steered towards patient benefit. We have found their open, honest and regular communication and flexibility to be of great benefit through the past year. We look forward to continuing the relationship and further realizing returns on AICR-funded research for people affected by cancer.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

First Treatment Approved Under EAMS
New immunotherapy (pembrolizumab) made available in the UK for treatment of adults with advanced melanoma.
Friday, March 13, 2015
Breakthrough Melanoma Treatment, Keytruda, Developed
New immunotherapy launched in the US for treatment of adults with advanced melanoma, developed using antibody humanization expertise at UK’s MRC Technology.
Friday, September 05, 2014
MRC Technology and IBP CAS Collaboration Yields Humanized Anti-CD146 Antibody
Antibody inhibits tumour angiogenesis, migration and invasion.
Wednesday, March 20, 2013
Scientific News
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
CRISPR-Cas9 Gene Editing: Check Three Times, Cut Once
Two new studies from UC Berkeley should give scientists who use CRISPR-Cas9 for genome engineering greater confidence that they won’t inadvertently edit the wrong DNA.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos